期刊文献+

厄贝沙坦联合美托洛尔治疗心力衰竭疗效分析及对血清脑钠肽水平的影响 被引量:7

Analysis of treatment effects and BNP detection in heart failure patients by Irbesartan and Metoprolol
原文传递
导出
摘要 目的探讨厄贝沙坦联合美托洛尔治疗心力衰竭的疗效及对血清脑钠肽(BNP)水平的影响。方法选取慢性充血性心力衰竭患者187例,随机分为观察组94例,对照组93例。对照组给予强心、利尿治疗。治疗组此基础上加用厄贝沙坦、美托洛尔。治疗前后检测BNP含量。结果治疗后观察组总有效率高于对照组(P〈0.05)。治疗后,观察组与对照组BNP均较治疗前显著降低(均P〈0.05)。治疗前后BNP减少值观察组高于对照组(P〈0.05)。结论CHF患者在常规治疗基础上,联合应用厄贝沙坦及美托洛尔,能有效提高疗效,降低血清BNP水平,显著改善心功能。 Objective To investigate the irbesartan combined with metoprolol in the treatment of congestive heart failure and effects on serum Brainnatriuretic peptide. Methods 187 patients with chronic congestive heart fail- ure (CHF),were randomly divided into the observation group 94 cases, 93 cases of the control group. The control group was given the strong heart, diuresis therapy. The treatment group on the basis of combined with irbesartan, meto- prolol. The content of BNP was detected before and after treatment. Results After treatment, the observation group to- tal efficiency is higher than that of the control group, the difference was statistically significant( P 〈 0.05 ). After treat- ment, the observation group and the control group of BNP were significantly lower, the difference was statistically sig- nificant(P 〈0.05 ). Before and after treatment with BNP reduced value comparison between groups, the observation group than in the control group, the difference was statistically significant ( P 〈 0.05 ). Conclusion The patients with CHF on the basis of routine treatment, combined with irbcsartan and metoprolol, can effectively improve the curative effect, decrease the serum level of BNP,improve heart function.
作者 何卫华
出处 《中国基层医药》 CAS 2012年第22期3367-3368,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 厄贝沙坦 美托洛尔 心力衰竭 Irbesartan Metoprolol Heart failure
  • 相关文献

参考文献10

二级参考文献90

共引文献6205

同被引文献76

  • 1陈秀梅,卢新政.利尿剂降压治疗的再认识[J].中华高血压杂志,2010,18(7):620-623. 被引量:6
  • 2HuangQ F, Sheng C S,Li Y,et al. Efficacy and safety of afixed combination of irbesartan/hydrochlorothiazide in Chinese pa-tients with moderate to severe hypertension [J]. Drugs in R&d,2013,13(2):109-117.
  • 3GreathouseM K, Weir M R. The role of ARBs alone or withHCTZ in the treatment of hypertension and prevention of cardio-vascular and renal complications [J]. Postgrad Med,2012,124(2):40-52.
  • 4Dussol B,Moussi - Frances J,Morange S, et al. A pilot studycomparing furosemide and hydrochlorothiazide in patients with hy-pertension and stage 4 or 5 chronic kidney disease [J]. The Journalof Clinical Hypertension,2012,14(1):32-37.
  • 5Stuart B,Loh F E, Magder L, et al. Anticipating Part D PhaseChanges : How Heart Failure Patients Respond to the MedicareDrug Benefit Design[J].J Pharma Care Health Sys,2014,1(104): 2.
  • 6Maniadakis N, Ekman M, Fragoulakis V, et al. Economic e-valuation of irbesartan in combination with hydrochlorothiazide inthe treatment of hypertension in Greece [J]. The European Journalof Health Economics,2011,12(3):253-261.
  • 7Agabiti-Rosei E, Manolis A, Zava D, et al. Zofenopril PlusHydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide inPreviously Treated and Uncontrolled Diabetic and Non 一diabeticEssential Hypertensive Patients [J]. Advances in therapy,2014,31(2): 217-233.
  • 8A1Balushi K A, Habib J Q,Al-Zakwani I. Comparative effi-cacy of irbesartan/hydrochlorothiazide and valsartan/hydrochloroth-iazide combination in lowering blood pressure : a retrospective ob-servational study in Oman [J]. Medical Principles and Practice,2012, 22(3):265-269.
  • 9李昭华,钟远伦.美托洛尔联合卡托普利治疗慢性心力衰竭的疗效观察[J].中国现代医生,2008,46(27):27-28. 被引量:9
  • 10陈芳,杨剑雪,周纪宁,王芳,杨波.倍他乐克对充血性心力衰竭患者P波离散度的影响[J].实用医学杂志,2009,25(1):130-132. 被引量:9

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部